RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Graft Versus Host Disease: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Erratum: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation.
Al Malki Monzr M et al., Journal of clinical oncology : official journal of the American Society of Clinical Oncology (20 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42748388/
- 2.
Outcomes of Allogeneic Stem Cell Transplantation in a North American Adult T Cell Leukemia/Lymphoma Cohort.
Wang Trent Peng et al., Transplantation and cellular therapy (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42892554/
- 3.
Axatilimab for Treatment of Patients With Oral Chronic Graft-Versus-Host Disease: A Post Hoc Analysis of the AGAVE-201 Study
Jacqueline Wiesehan Mays et al., Oral Surgery Oral Medicine Oral Pathology and Oral Radiology (15 October 2026)
https://doi.org/10.1016/j.oooo.2026.08.062
- 4.
IL-6 receptor inhibition promotes expansion of cytolytic CD4+ T cells after cellular immunotherapy.
Williams Cameron G et al., Blood (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42485668/
- 5.
Erratum to "Dietary stearic acid aggravates acute graft-versus-host disease by promoting oxidative stress and pro-inflammatory macrophage polarization" [Int. Immunopharmacol. 186 (2026) 117124].
Du Yue et al., International immunopharmacology (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42637610/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
NCT07118254 · Recruiting · Phase 2 · Lubris Bio Pty Ltd
Ages 18 to 75
https://clinicaltrials.gov/study/NCT07118254
- 2.
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774 · Recruiting · Phase 3 · Incyte Corporation
Ages 12 and over
https://clinicaltrials.gov/study/NCT06585774
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Graft Versus Host Disease
Graft versus host disease happens when immune cells from a donor stem cell or bone marrow transplant treat the recipient's body as foreign and attack it. It commonly affects the skin, gut, liver, eyes and mouth, and may come on soon after the transplant or develop slowly over months. Treatment uses steroids and other medicines that calm the donor immune cells, along with supportive care from a transplant team.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Graft Versus Host Disease?
Graft versus host disease happens when immune cells from a donor stem cell or bone marrow transplant treat the recipient's body as foreign and attack it. It commonly affects the skin, gut, liver, eyes and mouth, and may come on soon after the transplant or develop slowly over months. Treatment uses steroids and other medicines that calm the donor immune cells, along with supportive care from a transplant team.
How many clinical trials are available for Graft Versus Host Disease?
RareWays currently indexes 668 clinical trials for Graft Versus Host Disease, of which 86 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Graft Versus Host Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Graft Versus Host Disease.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.